Skip to Content

Another Bust for Alzheimer’s Drugs

Although Eli Lilly’s anti-amyloid compound fails to slow decline in two large trials, patients with mild forms of the disease show some benefit

For the second time this summer, a candidate drug has failed to slow the rate of mental decline in large trials of patients with Alzheimer’s disease. But some hope remains that the compound could help patients with milder forms of the disease.

On Friday, Eli Lilly announced that two late-stage trials of its amyloid-grabbing antibody solanezumab did not protect patients’ cognitive abilities. The results come just weeks after Pfizer and Johnson & Johnson announced their anti-amyloid antibody bapineuzumab failed in clinical trials (see “A New Setback for Alzheimer’s Drugs”).

However, when the data from both of Eli Lilly’s trials was pooled together, the company says its compound was able to slow decline in patients with mild forms of the disease. If that suggestion proves true, then it would lend support to the idea that amyloid-fighting drugs need to be administered early. Recent studies show that changes in the brain begin long before dementia sets in (see “An Alzheimer’s Warning 25 Years Before Symptoms Show”), so early treatment may be key to preventing permanent damage.

There is no cure for Alzheimer’s disease, which progressively robs patients of their memory and thinking abilities. The cause of the disease is unknown. But because the brains of Alzheimer’s patients are riddled with amyloid plaques– clumps of a piece of the amyloid protein– many see amyloid as a culprit and therapeutic target. Eli Lilly, Pfizer and Johnson & Johnson had all placed multi-million dollar bets on the amyloid hypothesis with the hope that their compounds would clear or block the formation of amyloid plaques in the brain.

According to a statement from Jan Lundberg, president of Lilly Research Laboratories, Eli Lilly thinks the results of the combined trial data validate that gamble:

“We believe the pooled data support the amyloid hypothesis, as these are the first Phase 3 data with an anti-beta amyloid agent that appear to show a slowing of cognitive decline.

The Alzheimer’s Disease Cooperative Study will present the results of its independent analyses of the solanezumab data in Boston in early October.

Keep Reading

Most Popular

individual aging affects covid outcomes concept
individual aging affects covid outcomes concept

Anti-aging drugs are being tested as a way to treat covid

Drugs that rejuvenate our immune systems and make us biologically younger could help protect us from the disease’s worst effects.

Europe's AI Act concept
Europe's AI Act concept

A quick guide to the most important AI law you’ve never heard of

The European Union is planning new legislation aimed at curbing the worst harms associated with artificial intelligence.

Uber Autonomous Vehicles parked in a lot
Uber Autonomous Vehicles parked in a lot

It will soon be easy for self-driving cars to hide in plain sight. We shouldn’t let them.

If they ever hit our roads for real, other drivers need to know exactly what they are.

crypto winter concept
crypto winter concept

Crypto is weathering a bitter storm. Some still hold on for dear life.

When a cryptocurrency’s value is theoretical, what happens if people quit believing?

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.